The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Merck
Stock and Other Ownership Interests - Merck
BELLWAVE-010: A phase 3 study of nemtabrutinib plus venetoclax versus venetoclax plus rituximab (VR) in previously treated patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
 
Muhit Ozcan
Research Funding - Abbvie; Acerta Pharma/AstraZeneca; Bayer; BeiGene; Dr. Reddy's Laboratories; Janssen; Lilly; Merck; Pfizer; Roche; Takeda
Travel, Accommodations, Expenses - Abbvie; MSD; Sandoz
 
David Lavie
Consulting or Advisory Role - Abbvie; Novartis; Roche; Takeda
Travel, Accommodations, Expenses - Abbvie
 
Arvind Chaudhry
Stock and Other Ownership Interests - Novartis and Immunomedics
Research Funding - Merck, Roche, AstraZeneca, Bayer, Beigene, Exelixis, Medilink, Mersana, Abbvie, Gilead, Arcus
 
Xuan Zhou
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Ima Paydar
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Mohammed Z.H. Farooqui
No Relationships to Disclose
 
Paolo Ghia
Honoraria - Abbvie; AstraZeneca; BeiGene; Galapagos NV; Gilead Sciences; Janssen Oncology; Juno/Celgene/Bristol-Myers Squibb; Lilly; MSD; Roche
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene/Juno; Galapagos NV; Galapagos NV; Janssen; Lilly; MSD; Roche
Research Funding - Abbvie; AstraZeneca; Bristol-Myers Squibb/Celgene/Juno (Inst); Janssen Oncology